Canadian CANNAINVESTOR Magazine December 2017 | Page 84

144

Louis Kyron: CCIM

Chris Bunka: LXX

CSE: LXX

OTCQB: LXRP

LXX: Our licenses are long-term contracts generally of 2-5 years. Whether Lexaria is at some point taken over or not, these contracts remain valid and Lexaria is obligated to honour them. If Lexaria is ever acquired by a third party, then at the very least the duration of these contracts remains in force.

CCIM: When last we spoke, Lexaria had announced the study to be undertaken by the University of British Columbia. Can you update us on timelines for milestones and completion?

LXX: Yes all the components of the study have now been manufactured: the placebo; the positive control; and the TurboCBD to be studied. Study design is complete and final quality control testing is nearly complete and this study could begin at any time, subject only to the capacity of the study lab. We would hope to have our first internal data very early in the New Year and the entire study should be complete late in the winter.

CCIM: Somewhat related, where is Lexaria with respect to the laboratory work with the National Research Council?

LXX: Early-phase work has been completed on related molecules to gain greater lab understanding of the processes involved. Second-phase design is underway and should be finalized soon. Keep in mind this was originally developed as an 18-month study and we are about six months into it. We expect and hope to be working with the NRC throughout 2018 and 2019 on this and additional characterization work.

CCIM: The last six months have been a whirlwind of news and milestones … can we expect a slowdown or are we in for another torrid six months?

LXX: If anything, I expect an acceleration of development from Lexaria. Think about it this way: it was really difficult for us to ask/expect any partner company to actually “pay-up” for a Dehyra-TECHTM license prior to the patent actually being allowed by the USPTO. We only just announced that development on November 1, so the starting pistol only just fired then. But our patent applications are still pending in China, Canada, the EU, India and more. If and as we receive patent grants in these countries our tech only becomes more and more valuable. For example during the last three months or so, we’ve been informed that some of our earliest patent applications have entered the “active investigation” phases in Canada, China, and the EU. I expect a flurry of patent news throughout 2018 and, on the hells of that, a number of significant commercial licensing agreements that will start to deliver important revenue streams to Lexaria.

84